10.1 Neonatal Seizures & Pediatric Status Epilepticus

10.1 Neonatal Seizures & Pediatric Status Epilepticus

Seizure management across the pediatric continuum spans two distinct clinical landscapes: the physiologically unique neonate encountering immature excitation-inhibition dynamics, and the child or adolescent presenting with life-threatening status epilepticus. Pediatric clinical specialists must master developmental neurobiology, evidence-based algorithmic escalations, and therapeutic drug monitoring to prevent irreversible excitotoxic brain injury.

---

Neonatal Seizure Pathophysiology & Etiologies

Neonatal seizures occur in approximately 1.5 to 3.5 per 1,000 live term births and up to 10 to 130 per 1,000 preterm births. Unlike older pediatric patients who present with coordinated generalized tonic-clonic convulsions, neonates possess immature cerebral myelination, dendritic branching, and synaptogenesis. Consequently, neonatal seizures are predominantly focal, multifocal, or subtle (e.g., rhythmic eye deviation, bicycling movements, oral-buccal sucking, or episodic paroxysmal apneas with tachycardia).

Developmental Chloride Transporter Ontogeny in Immature Neurons:

Immature Neonatal Neuron:                               Mature Pediatric/Adult Neuron:
┌─────────────────────────────────────────┐             ┌─────────────────────────────────────────┐
│ High Intracellular [Cl-] (~30-40 mmol/L)│             │ Low Intracellular [Cl-] (~5-10 mmol/L)  │
│                                         │             │                                         │
│     [NKCC1 Influx] > [KCC2 Efflux]      │             │      [KCC2 Efflux] > [NKCC1 Influx]     │
│               │                         │             │               │                         │
│               ▼                         │             │               ▼                         │
│   GABA-A Receptor Activation            │             │   GABA-A Receptor Activation            │
│               │                         │             │               │                         │
│               ▼                         │             │               ▼                         │
│  Chloride EFFLUX (Depolarization)       │             │   Chloride INFLUX (Hyperpolarization)   │
│      EXCITATORY EFFECT                  │             │       INHIBITORY EFFECT                 │
└─────────────────────────────────────────┘             └─────────────────────────────────────────┘

The Immature GABAergic Switch

The fundamental electrophysiological paradox of the neonatal brain centers on the chloride ion equilibrium potential:

• NKCC1 Cotransporter Dominance: In immature cortical neurons, the sodium-potassium-chloride cotransporter 1 (NKCC1) is highly expressed, actively pumping chloride into the intracellular space. Concurrently, the potassium-chloride cotransporter 2 (KCC2), which extrudes chloride, is developmentally deficient.
• Paradoxical Depolarization: Intracellular chloride concentration is markedly elevated (30 to 40 mmol/L vs. 5 to 10 mmol/L in mature neurons). When γ-aminobutyric acid (GABA) binds to GABA-A receptors, opening ligand-gated chloride channels, chloride flows out of the neuron along its concentration gradient. This cellular loss of negative charge produces membrane depolarization and neuronal excitation rather than hyperpolarizing inhibition.
• Clinical Relevance: Despite this immature excitatory shift in select neuronal sub-populations, phenobarbital remains the most effective, proven first-line agent, though overall single-agent efficacy in terminating electrographic neonatal seizures is only approximately 40% to 50%.

Primary Etiologies of Neonatal Seizures

1. Hypoxic-Ischemic Encephalopathy (HIE): Accounts for 50% to 60% of all neonatal seizures. Seizures typically present within the first 12 to 24 hours of life following intrapartum asphyxia. Managed with therapeutic hypothermia (33.5°C for 72 hours) combined with anticonvulsant therapy.
2. Intracranial Hemorrhage & Stroke: Includes intraventricular hemorrhage (IVH, common in very low birth weight preterms), subarachnoid hemorrhage, and perinatal arterial ischemic stroke (frequently presenting with focal clonic limb jerking at 48 to 72 hours of life).
3. Acute Metabolic Disturbances: Transient hypoglycemia (serum glucose <40 to 45 mg/dL), hypocalcemia (ionized calcium <1.0 mmol/L), and hypomagnesemia (<1.5 mg/dL). These must be corrected immediately before escalating antiseizure medications.
4. Inborn Errors of Metabolism: Urea cycle defects (hyperammonemia), non-ketotic hyperglycinemia, maple syrup urine disease (MSUD), and organic acidemias.
5. Pyridoxine-Dependent Epilepsy: An autosomal recessive metabolic disorder caused by mutations in the ALDH7A1 gene encoding antiquitin (producing α-aminoadipic semialdehyde dehydrogenase deficiency). Accumulated semialdehyde inactivates pyridoxal 5'-phosphate (PLP, the active cofactor for glutamic acid decarboxylase), blocking GABA synthesis and producing severe, drug-resistant status epilepticus.

---

Pharmacotherapy of Neonatal Seizures

Neonatal Seizure Pharmacotherapy Algorithm:

Step 1: Check bedside glucose & electrolytes ──► Correct hypoglycemia / hypocalcemia
                          │
                          ▼ Seizures Continue
Step 2: PHENOBARBITAL IV: 20 mg/kg load over 20-30 min
        (Repeat 10-20 mg/kg if needed; max cumulative 40 mg/kg; target level 15-40 mcg/mL)
                          │
                          ▼ Seizures Continue
Step 3: LEVETIRACETAM IV: 40-60 mg/kg load over 10-15 min
        (Avoid fosphenytoin in preterms/neonates due to erratic prodrug bioactivation)
                          │
                          ▼ Seizures Continue (Refractory)
Step 4: PYRIDOXINE (Vit B6) IV Trial: 100 mg IV under continuous EEG
        (Have bag-valve-mask ready for acute apnea / hypotonia)

First-Line Agent: Phenobarbital

• Mechanism of Action: Positive allosteric modulator of GABA-A receptors. Increases the duration of chloride channel openings in the presence of GABA, dampening cortical excitability and raising seizure threshold.
• Loading Dose: 20 mg/kg IV administered over 20 to 30 minutes (infusion rate ≤ 1 mg/kg/min). If electrographic or clinical seizures persist after 15 to 30 minutes, additional boluses of 10 to 20 mg/kg may be administered up to a maximum cumulative loading dose of 40 mg/kg.
• Therapeutic Serum Concentration: 15 to 40 mcg/mL. Levels up to 40 mcg/mL are frequently required for electrographic seizure cessation.
• Neonatal Pharmacokinetics:
  • Prolonged Half-Life: In full-term neonates, the elimination half-life is 100 to 120 hours, extending to 150 to 200 hours in premature neonates or those undergoing therapeutic hypothermia (compared to 40 to 100 hours in older children and adults). This prolonged clearance results from immature hepatic cytochrome P450 isoenzymes (CYP2C9, CYP2C19, CYP2E1) and reduced glomerular filtration rate.
  • Maintenance Dosing: 3 to 4 mg/kg/day IV or oral administered once daily or divided every 12 hours, initiated 12 to 24 hours after the completion of the loading dose.
• Adverse Effects & Monitoring: Severe respiratory depression and hypopnea (especially when combined with benzodiazepines), hypotension (due to propylene glycol diluent and myocardial depression; requires slow infusion and continuous blood pressure monitoring), profound sedation, and potential disruption of neuronal apoptosis during peak synaptogenesis.

Second-Line Agent: Levetiracetam

• Mechanism: Binds selectively to presynaptic synaptic vesicle protein 2A (SV2A), modulating vesicular exocytosis of excitatory neurotransmitters (glutamate).
• Dosing in Neonates: Loading dose of 40 to 60 mg/kg IV over 10 to 15 minutes, followed by a maintenance dose of 30 to 60 mg/kg/day divided every 12 hours.
• Pharmacokinetics: Hydrophilic molecule with low plasma protein binding (<10%). Eliminated primarily unchanged via renal glomerular filtration (66%) and via non-hepatic enzymatic hydrolysis in circulating blood. Extremely clean drug-interaction profile (no CYP450 induction or inhibition).

Why Fosphenytoin / Phenytoin is Avoided in Neonates

Historically used as a second-line agent, fosphenytoin is now actively avoided in the neonatal intensive care unit (NICU):

1. Immature Prodrug Conversion: Fosphenytoin is a water-soluble phosphate ester prodrug that requires cleavage by endothelial and erythrocyte alkaline phosphatase to liberate active phenytoin. Neonatal alkaline phosphatase expression and catalytic efficiency are erratic, leading to unpredictable, delayed bioactivation and delayed therapeutic peak levels.
2. Altered Plasma Protein Binding: Phenytoin is normally 90% albumin-bound in adults. In neonates, reduced serum albumin levels (2.5–3.5 g/dL) and endogenous displacers (hyperbilirubinemia, maternal free fatty acids) elevate the free unbound fraction to 20% to 25% (double adult values). Monitoring total levels (reference range 10–20 mcg/mL) grossly misleads clinicians; a "normal" total level of 12 mcg/mL in a jaundiced neonate corresponds to a toxic free level of 2.5–3.0 mcg/mL (therapeutic free range: 1.0–2.0 mcg/mL).
3. Oral Absorption Failure: Enteral phenytoin is virtually unabsorbed in neonates due to gastric hypochlorhydria (pH > 4.0), which prevents dissolution of this weak acid (pKa ≈ 8.3), combined with insoluble chelation to infant formula calcium and casein.
4. Cardiovascular Collapse: Rapid infusions provoke severe hypotension, cardiac conduction blocks, and ventricular arrhythmias.

Pyridoxine (Vitamin B6) Trial Protocol

In any neonate with idiopathic, drug-resistant status epilepticus or familial neonatal epilepsy, an empiric trial of pyridoxine is mandatory:

• Administration: 100 mg IV administered as a single slow push under continuous bedside EEG and cardiorespiratory monitoring.
• Diagnostic Response: In true pyridoxine-dependent epilepsy, clinical and electrographic seizure discharges completely cease within minutes to 1 hour, with complete normalization of the background EEG within 24 to 72 hours.
• Critical Practice Alert: Intravenous administration of pyridoxine in responsive infants frequently triggers profound generalized hypotonia, hypothermia, bradycardia, and acute central apnea lasting several hours. The clinical team must have bag-valve-mask ventilation and endotracheal intubation equipment immediately at the bedside prior to initiating the infusion.
• Maintenance: If responsive, lifelong oral pyridoxine (15 to 30 mg/kg/day orally divided into 2 or 3 doses) is required.

---

Pediatric Status Epilepticus (AES / Neurocritical Care Guidelines)

Status epilepticus (SE) is defined operationally as ≥ 5 minutes of continuous convulsive seizure activity, or two or more discrete seizures between which there is incomplete recovery of baseline consciousness. Neuronal injury begins at 5 minutes, driven by excessive glutamate release, NMDA receptor hyperactivation, intracellular calcium influx, and mitochondrial failure. By 30 minutes, profound pharmacoresistance develops due to GABA-A receptor internalization into endosomes and compensatory upregulation of excitatory NMDA receptors on the postsynaptic membrane.

Pediatric Status Epilepticus Algorithmic Timeline:

0 - 5 min:   STABILIZATION PHASE
             • ABCs, high-flow O2, bedside blood glucose check
             • If glucose <60 mg/dL: Administer D10W 2 mL/kg IV bolus
             • Establish IV / IO access; continuous pulse oximetry, ECG

5 - 10 min:  EMERGENT INITIAL THERAPY (First-Line Benzodiazepines)
             • IV available: LORAZEPAM 0.1 mg/kg IV (max 4 mg, over 2 min)
             • NO IV access: MIDAZOLAM 0.2 mg/kg IM (max 10 mg) OR intranasal (0.2 mg/kg)
             • Alternative: DIAZEPAM 0.2 mg/kg IV (max 10 mg) or Rectal Gel 0.2-0.5 mg/kg
             • May repeat ONCE at 5-10 min if seizure continues

10 - 30 min: URGENT CONTROL THERAPY (Second-Line Non-Sedating ASMs)
             • ESETT Trial Options (Equally efficacious ~50%):
               - LEVETIRACETAM: 60 mg/kg IV (max 4500 mg) over 10 min
               - FOSPHENYTOIN:  20 mg PE/kg IV (max 1500 mg PE) at ≤150 mg PE/min
               - VALPROATE NA:  40 mg/kg IV (max 3000 mg) over 10 min

> 30 min:    REFRACTORY STATUS EPILEPTICUS (Third-Line Continuous Anesthetics)
             • Secure airway (endotracheal intubation); initiate continuous cEEG
             • MIDAZOLAM: Load 0.2 mg/kg IV, then 0.1-2 mg/kg/hr infusion
             • PENTOBARBITAL: Load 5 mg/kg IV, then 1-5 mg/kg/hr (titrate to burst suppression)
             • Avoid prolonged PROPOFOL infusion due to PRIS risk

Phase 1: Stabilization (0 to 5 Minutes)

• Airway, breathing, circulation (ABCs); deliver 100% high-flow supplemental oxygen via non-rebreather mask.
• Immediate point-of-care blood glucose determination. If blood glucose is <60 mg/dL, immediately administer Dextrose 10% in water (D10W) 2 mL/kg IV bolus (equivalent to 0.2 g/kg dextrose). Avoid concentrated D50W in pediatrics due to extreme hyperosmolality (2,525 mOsm/L) and sclerosing venous injury.
• Secure intravenous (IV) or intraosseous (IO) access; obtain stat serum electrolytes, calcium, magnesium, venous blood gas, and baseline anticonvulsant levels.

Phase 2: Emergent Initial Therapy (5 to 10 Minutes)

First-line therapy is a rapidly acting parenteral benzodiazepine. Prompt administration is paramount; delay beyond 10 minutes significantly decreases drug efficacy:

• Intravenous Access Present: Lorazepam 0.1 mg/kg IV (maximum single dose: 4 mg), administered slow push over 2 minutes. Lorazepam is favored for IV use due to lower lipid solubility than diazepam, resulting in less rapid redistribution out of the central nervous system and a prolonged effective anticonvulsant duration of 4 to 6 hours.
• No Intravenous Access: Midazolam 0.2 mg/kg intramuscularly (IM) (maximum single dose: 10 mg) is the preferred evidence-based first-line agent, established by the landmark RAMPART trial (demonstrating IM midazolam via autoinjector was superior to IV lorazepam in prehospital cessation due to rapid administration without IV placement delays). Alternatively, intranasal midazolam (0.2 mg/kg, using concentrated 5 mg/mL formulation divided equally between nostrils with a mucosal atomization device [MAD]) or buccal midazolam (0.2–0.5 mg/kg).
• Alternative Agents: Diazepam 0.2 mg/kg IV (max 10 mg) or Rectal Diazepam Gel (Diastat): 0.2 to 0.5 mg/kg based on age (0.5 mg/kg for 2–5 yr, 0.3 mg/kg for 6–11 yr, 0.2 mg/kg for ≥ 12 yr; max 20 mg).
• Re-Dosing: If seizures continue at 5 to 10 minutes post-administration, repeat the benzodiazepine dose once. If seizures persist beyond 10 minutes, immediately proceed to Phase 3. Do not administer more than two doses of benzodiazepines due to steep increases in respiratory depression, hypercapnia, and hypotension.

Phase 3: Urgent Control / Established SE (10 to 30 Minutes)

If the seizure persists despite two adequate doses of benzodiazepines, the patient has established status epilepticus. Second-line non-sedating intravenous anticonvulsants must be initiated without delay.

The Landmark ESETT Trial (2019)

The Established Status Epilepticus Treatment Trial (ESETT) was a multicenter, randomized, blinded, comparative-effectiveness trial evaluating patients aged 2 to 30+ years (including extensive pediatric enrollment) who failed first-line benzodiazepines. ESETT compared three IV agents targeting seizure cessation at 60 minutes with improved responsiveness and no rescue therapy:

ESETT Clinical Verdict: All three agents demonstrated equivalent efficacy (terminating seizures in approximately half of all patients) with no statistically significant differences in safety or adverse events. Agent selection is therefore dictated by patient-specific clinical contraindications:

• Select Levetiracetam for patients with acute liver injury, hemodynamic instability, or cardiac conduction abnormalities.
• Avoid Valproate sodium in children under 2 years of age or any patient with suspected inborn errors of metabolism or mitochondrial DNA polymerase gamma (POLG) mutations due to fatal fulminant hepatic necrosis.
• Ensure Fosphenytoin is infused strictly at ≤ 150 mg PE/min with continuous electrocardiographic (ECG) and non-invasive blood pressure monitoring.

Phase 4: Refractory Status Epilepticus (>30 Minutes)

Patients who continue seizing after adequate second-line therapy have refractory status epilepticus (RSE). This requires immediate endotracheal intubation, mechanical ventilation, invasive arterial line hemodynamic monitoring, continuous continuous EEG (cEEG), and transfer to a Pediatric Intensive Care Unit (PICU).

1. Midazolam Continuous Infusion:
   • Loading Dose: 0.2 mg/kg IV slow bolus (may repeat 0.1 to 0.2 mg/kg every 5 minutes until seizures stop, up to max cumulative load 2 mg/kg).
   • Infusion Rate: Initiate at 0.1 to 0.2 mg/kg/hr; titrate by 0.1 mg/kg/hr every 15 minutes to electrographic seizure cessation (usual effective range: 0.2 to 1.0 mg/kg/hr; maximum: 2.0 mg/kg/hr).
   • Tachyphylaxis: Rapid development of tolerance is common after 24 to 48 hours due to GABA-A receptor down-regulation, requiring progressive upward dose titration.
2. Pentobarbital Continuous Infusion:
   • Loading Dose: 5 mg/kg IV administered over 10 minutes.
   • Infusion Rate: 1 to 5 mg/kg/hr titrated to target EEG burst suppression with an inter-burst interval of 10 to 15 seconds.
   • Adverse Effects: Profound myocardial depression, systemic vasodilation, and decreased venous return requiring aggressive crystalloid resuscitation and continuous vasopressor infusions (dopamine, epinephrine, or norepinephrine); paralytic ileus; loss of corneal/pupillary reflexes.
3. Propofol & Propofol Infusion Syndrome (PRIS) Caution:
   • While propofol is a potent GABA-A agonist and NMDA blocker, it is strictly avoided for prolonged infusions in pediatrics.
   • PRIS Pathogenesis: Uncoupling of the mitochondrial electron transport chain and impaired fatty acid oxidation. Characterized by severe refractory metabolic acidosis, rhabdomyolysis, hyperkalemia, hepatomegaly, hyperlipidemia, renal failure, and rapidly fatal myocardial collapse.
   • Pediatric Rule: Propofol infusions exceeding 4 to 5 mg/kg/hr (67–83 mcg/kg/min) or lasting longer than 48 hours are contraindicated in pediatric patients.

---

Practice Pearls & BCPPS Exam Traps

• Exam Trap 1: Do not administer phenytoin or fosphenytoin orally for maintenance in neonates; oral bioavailability is near zero due to neutral gastric pH and precipitation with milk formulas.
• Exam Trap 2: Never exceed the fosphenytoin infusion rate limit of 150 mg PE/min in adolescents or 3 mg PE/kg/min in younger children. Exceeding this rate induces severe bradycardia, QTc prolongation, and asystole.
• Board Rule: Total phenytoin serum levels in neonates and hypoalbuminemic pediatric patients are unreliable. Calculate free phenytoin or order direct unbound levels. Equation: Adjusted Total Phenytoin = Reported Total / (0.2 × Albumin + 0.1) (or assume free fraction = 0.20–0.25 in neonates).
• Exam Trap 3: In status epilepticus, do not waste critical time placing an IV if access is difficult. Intramuscular midazolam (0.2 mg/kg, max 10 mg) into the anterolateral thigh delivers rapid, life-saving therapeutic brain concentrations faster than protracted IV attempts.